Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations at proximal cysteine residues in PML impair ATO binding by destabilizing the RBCC domain.

The FEBS journal - 1 Apr 2024

Dubey Suchita, Mishra Neha, Shelke Rohan, Varma Ashok K

Abstract excerpt

Acute promyelocytic leukemia (APL) is characterized by the fusion gene promyelocytic leukemia-retinoic acid receptor-alpha (PML-RARA) and is conventionally treated with arsenic trioxide (ATO). ATO binds directly to the RING finger, B-box, coiled-coil (RBCC) domain of PML and initiates degradation of the fusion oncoprotein PML-RARA. However, the mutational hotspot at C212-S220 disrupts ATO binding, leading to drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Arsenic Trioxide
Share to Arsenicals

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cysteine

Share to Drug Resistance, Neoplasm

Share to Leukemia, Promyelocytic, Acute

Share to Oncogene Proteins, Fusion

Share to Oxides

Source

Identifiers

PMID: 38129745
DOI: 10.1111/febs.17041

Genes

PML
RARA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations at proximal cysteine residues in PML impair ATO binding by destabilizing the RBCC domain.PMID 38129745Read ↗

Altered nuclear cofactor switching in retinoic-resistant variants of the PML-RARα oncoprotein of acute promyelocytic leukemia.Semantic proximity Read ↗

Varying responses of PML-RARA with different genetic mutations to arsenic trioxideSemantic proximity Read ↗

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Semantic proximity Read ↗

Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site.Semantic proximity Read ↗

Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemiaSemantic proximity Read ↗

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatmentSemantic proximity Read ↗

Modulation of conformational features and oligomerization of MMACHC by cobalamin variants: impact of the R161Q mutation in cblC disease.Semantic proximity Read ↗

Phenylarsine Oxide Can Induce the Arsenite-Resistance Mutant PML Protein Solubility Changes.Semantic proximity Read ↗

Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.Semantic proximity Read ↗

Critical role of tripartite fusion and LBD truncation in certain RARA- and all RARG-related atypical APLSemantic proximity Read ↗

Interplay of protein disorder in retinoic acid receptor heterodimer and its corepressor regulates gene expressionSemantic proximity Read ↗

Transporter-to-trap conversion: a disulfide bond formation in cellular retinoic acid binding protein I mutant triggered by retinoic acid binding irreversibly locks the ligand inside the protein.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.